Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ekso Bionics Holdings (EKSO) EBIT Margin (2016 - 2026)

Ekso Bionics Holdings has reported EBIT Margin over the past 13 years, most recently at 143.6% for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 9979.0% to 143.6% in Q4 2025 year-over-year; TTM through Dec 2025 was 104.12%, a 4576.0% decrease, with the full-year FY2025 number at 104.12%, down 4576.0% from a year prior.
  • EBIT Margin reached 143.6% in Q4 2025 per EKSO's latest filing, down from 33.17% in the prior quarter.
  • The five-year high for EBIT Margin was 33.17% in Q3 2025, with the low at 193.24% in Q2 2025.
  • The 5-year median for EBIT Margin is 99.46% (2022), against an average of 103.15%.
  • Peak YoY movement for EBIT Margin: soared 16134bps in 2021, then tumbled -14607bps in 2025.
  • Tracing EKSO's EBIT Margin over 5 years: stood at 111.68% in 2021, then dropped by -12bps to 124.92% in 2022, then surged by 43bps to 71.16% in 2023, then soared by 38bps to 43.81% in 2024, then plummeted by -228bps to 143.6% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 143.6%, 33.17%, and 193.24% for Q4 2025, Q3 2025, and Q2 2025 respectively.